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Circulating permeability factors have been identiﬁed in the plasma of patients with
focal segmental glomerulosclerosis (FSGS). Post-transplant recurrence of protei-
nuria, improvement of proteinuria after treatment with plasmapheresis, and
induction of proteinuria in experimental animals by plasma fractions each provide
evidence for such plasma factors. Advanced proteomic methods have identiﬁed
candidate molecules in recurrent FSGS. We have proposed cardiotrophin-like
cytokine-1 as an active factor in FSGS. Another potential permeability factor in
FSGS is soluble urokinase receptor. In our studies, in vitro plasma permeability
activity is blocked by substances that may decrease active molecules or block their
effects. We have shown that the simple sugar galactose blocks the effect of FSGS
serum in vitro and decreases permeability activity when administered to patients.
Since the identities of permeability factors and their mechanisms of action are not
well deﬁned, treatment of FSGS is empiric. Corticosteroids are the most common
agents for initial treatment. Calcineurin inhibitors, such as cyclosporine A, and
tacrolimus and immunosuppressive medications, including mycophenylate, induce
remission is some patients with steroid-resistant or -dependent nephrotic syn-
drome. Therapies that diminish proteinuria and slow progression in FSGS as well as
other conditions include renin-angiotensin blockade, blood pressure lowering and
plasma lipid control. Use of ﬁndings from in vitro studies, coupled with deﬁnitive
identiﬁcation of pathogenic molecules, may lead to new treatments to arrest FSGS
progression and prevent recurrence after transplantation.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Focal segmental glomerulosclerosis (FSGS) is a pathological
diagnosis that has been used to describe renal biopsies from
patients with widely varying clinical presentations and etiolo-
gies. Patients may present with or without nephrotic syndrome,
may or may not have remission of proteinuria after treatmentrean Society of Nephrology. P
ses/by-nc-nd/4.0/).
al Center, 4801 Linwood
savin@va.gov (VJ Savin).with corticosteroids, and may experience slow or rapid decline
in glomerular ﬁltration rate. It is often not possible to deter-
mine whether an individual has FSGS or a more benign form of
idiopathic nephrotic syndrome, such as minimal change
nephrotic syndrome (MCNS), at the time of presentation. This
fact, and the common practice of deferring renal biopsy until
the patient has proven that they are resistant to treatment with
corticosteroids, has led to some confusion in interpreting
reports regarding the etiology, treatment, and outcomes in
patients with nephrotic syndrome. Studies of both familial
and sporadic cases have revealed that glomerular injury in aublished by Elsevier. This is an open access article under the CC BY-NC-
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podocyte junctions, change the cytoskeleton or attach to the
extracellular matrix, alter ion channels in ways that increase
the energy demands of cells, or impair mitochondrial function.
Viral infection and toxins have also been identiﬁed in FSGS.
Finally, as exempliﬁed by patients who experience recurrent
proteinuria and glomerular disease after renal transplantation,
circulating substances that interact with podocytes may cause
FSGS. Experimental studies have identiﬁed podocyte mechan-
isms that protect or limit damage from exogenous stressors.
In this review, we will brieﬂy summarize the major
genetic abnormalities in familial FSGS and touch upon the
potential role of viral infection. We will discuss several
agents that have been proposed as important causes of
proteinuria in FSGS, and examine strategies to remove these
substances or prevent their accumulation. We will also
discuss therapies that may enhance glomerular defenses
and protect the kidney from the cumulative injury respon-
sible for progression to renal failure.Clinical course and therapy
FSGS has a highly variable course; some of this variation
may occur because of the diversity of etiologies, variation in
host or environmental factors or due to attempts at therapy.
Few trials have included segregation by genetic testing, age or
renal function at diagnosis or severity of proteinuria, and
thus many do not offer the speciﬁc information required to
individualize therapy. No randomized controlled trials of
sufﬁcient numbers of patients are available to provide high
quality information to guide therapy of FSGS in either native
kidneys or renal allografts.
Current therapy results in full or partial remission in only
about 50% of patients. Treatments that have been employed
include corticosteroids with or without cyclophosamide [1],
cyclosporine A [2,3], tacrolimus [4,5], mycophenolate mofetil
[6], rituximab [7,8] and adrenocorticotropic hormone [9]. If
proteinuria can be reduced by these agents or by nonspeciﬁc
therapies such as angiotensin converting enzyme inhibitors,
angiotensin receptor blockers, aldosterone inhibitors and/or
lipid-lowering agents, the progression of renal dysfunction is
slowed [10]. Patients who are young at the time of diagnosis
and those of any age who progress rapidly to end-stage renal
disease have an increased incidence of post-transplant recur-
rence of proteinuria and FSGS [11].
Regardless of the etiology of FSGS, current and proposed
therapies include three general strategies:(i) identifying and
reversing the primary cause of renal injury; (ii) decreasingTable 1. Presentations of genetic abnormalities associated with FSGS
Age at onset Histology
Congenital Dilated tubules
Minimal change or FSGS
Mesangial sclerosis
Young children Minimal change or FSGS
Mesangial sclerosis
Children or adults FSGS
Table adapted from [83].proteinuria by interventions relating to hemodynamic para-
meters and/or glomerular cellular responses; and (iii) slowing
renal scarring by the action of nonspeciﬁc agents that target
pathways for inﬂammation or ﬁbrosis. Current research studies
using animal models and clinical trials are aimed at identifying
novel therapies that will address each of these strategies.Genetic causes of FSGS
The discovery of nephrin deﬁciency as the cause of con-
genital nephrotic syndrome [12] has led to the intensive study
of podocyte proteins and function and the identiﬁcation
of additional gene alterations in proteinuric renal disease and
glomerulosclerosis. In Finnish nephropathy, nephrin, the major
protein of the slit-pore junction, is not expressed and slit-
diaphragms are absent. The majority of gene mutations that
have been identiﬁed and result in nephrotic syndrome and
FSGS alter podocyte proteins related to the slit-junction com-
plex or to control of the actin cytoskeleton [13]. Abnormal
podocin and a-actinin 4 are the most common, while muta-
tions in Neph 2, CD2AP, podoplanin, inverted formin-2, phos-
pholipase Ce1, and others affect a smaller number of families
and individuals. In addition, an abnormal ion channel (TRPC 6)
that causes enhanced and prolonged calcium signaling has
been discovered in several families with late onset FSGS [14].
Disorders of mitochondrial function and other genetic disor-
ders are also associated with FSGS. Clinical presentation
provides clues to the classiﬁcation of different disorders and
genetic testing for the more common mutations is commer-
cially available. Interpretation of genetic results is complicated
by the fact that many novel mutations are being identiﬁed and
their relationship to disease in an individual patient cannot
always be determined. Some general guidelines for differen-
tiating between common disorders are shown in Table 1.Viruses and nephrotoxins in FSGS
Glomerular injury, proteinuria, and progressive renal fail-
ure were identiﬁed in patients with HIV early in the study of
HIV/AIDS. HIV-associated nephropathy (HIVAN) may occur
even prior to the expression of HIV antibodies, and may be
reversed with highly active antiretroviral therapy [15]. More
often, HIVAN is detected in patients with established disease
and may progress despite successful therapy. The most
common histological lesions in HIVAN are collapsing glomer-
ulopathy and microcystic tubular lesions, but other glomeru-
lar lesions may occur in individual patients. Several accessoryAffected gene
Nephrin
Nephrin or podocin
Wilm’s tumor 1 (WT1), Phospholipase Ce1 (PLEC1)
Incidence: Podocin4Nephrin4WT14PLEC1
WT1, PLEC1
Recessive: Podocin
Dominant: WT1, PLEC1, aActinin 4, Inverted formin-2 (INF2)
Figure 1. Illustration of method for calculating glomerular albumin
permeability. Isolated glomeruli were subjected to a change in bathing
medium that resulted in inﬂux of ﬂuid into the capillaries and capillary
expansion. Glomerular diameter was measured and glomerular volume
was calculated as the volume of an ellipsoid. Volume increase in both
normal and injured glomeruli was directly proportional to the differ-
ence in oncotic pressures of the initial and ﬁnal media within the range
studied, but the slopes of these relationships differed. The ratio of
Table 2. Substances that prevent increase in Palb by FSGS patient sera
Blocking substance Proposed mechanism References
Normal plasma Competitive binding to receptor [23]
Eicosanoids: 20-HETE, 8,9 EET Unknown [24,25]
Indomethacin Cyclooxygenase (COX) inhibition [74]
Trypterygium wilfordii, glycoside Decreased oxidative stress; COX inhibition [76]
Sodium orthovanadate Tyrosine phosphatase inhibitor [22]
Cyclosporine A Serine phosphatase inhibitor, stabilizes synaptopodin phosphorylation [54]
Galactose Binds to and inactivates permeability factor [72]
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(VPR), may be sufﬁcient to cause HIVAN as shown in animal
models expressing nontransmissible virus [16].
Parvovirus has also been shown in the podocytes of some
patients with FSGS [17]. The relevance of this infection
to idiopathic FSGS is not fully understood. It is possible that
other viral infections may also lead to FSGS through their
effects on podocytes.
Toxins have been used to cause proteinuria and FSGS in
experimental animals. Agents employed include Adriamycin
and puromycin aminonucleoside, which have been used in
many studies to induce nephrotic syndrome or glomerulo-
sclerosis [18,19]. Puromycin aminonucleoside alters the
podocyte cytoskeleton and results in detachment. Bispho-
sphonates also act as podocyte toxins and produce collapsing
glomerulosclerosis in humans [20]. Toxicity appears to be
most common following parenteral administration of rather
high doses in patients with renal insufﬁciency. Dosing regi-
mens have been modiﬁed to decrease risk in patients with
impaired glomerular ﬁltration rate.slopes deﬁned the albumin reﬂection coefﬁcient. In the example
depicted, the reﬂection coefﬁcient for injured glomeruli is about 0.5.
In practice, a single gradient is used throughout an experiment.
Multiple animals are studied and results are averaged and subjected
to statistical analysis to determine differences among experimental
treatments. Palb is calculated as shown [21].Circulating factors
Circulating factor(s) in idiopathic FSGS and in post-transplant
recurrence
Our studies of glomerular permeability using isolated glo-
meruli have permitted us to test the immediate effects of a
number of substances that have been implicated as mediators of
injury by studies of intact animals. The assay that we developed
and have used in these studies is based on the fact that
transcapillary ﬁltration can be induced by creating an oncotic
gradient across the capillary wall. In our standard protocol,
glomeruli are isolated in isotonic medium containing 5% bovine
serum albumin and observed prior to and after a change of
medium to 1% bovine serum albumin [21]. The change in
bathing medium results in an oncotic gradient and causes net
ﬂuid ﬂow into the glomerular capillaries. Capillaries expand and
the entire glomerular image increases in size. Net ﬂuid ﬂow is
proportional to the effective oncotic gradient that, in turn, is the
product of the reﬂection coefﬁcient of the solute (s) and the
chemical oncotic gradient (DP). In the case of normal glomeruli,
s for albumin is one and the effective oncotic gradient equals
DP. When the permeability barrier is damaged, s decreases,
the effective gradient is diminished, and the increase in glo-
merular size (DV) is reduced proportionally. With the most
severe damage, the oncotic gradient is completely ineffective, no
net ﬂuid ﬂow occurs, and there is no capillary or glomerular
expansion (DV¼0; salb¼0). We have deﬁned albumin perme-
ability, Palb, as (1–salb). When constant conditions are used, Palb
can be calculated as 1–((DVexperimental)/(DVcontrol)). Palb is adimensionless parameter that increases from a normal value of
zero to a maximum of one with increasing severity of injury. The
relationship between the oncotic gradient applied and glomerular
volume increase and the calculations used are shown in Fig. 1.
We have shown that a medium containing serum or plasma
from patients with recurrent FSGS and from other FSGS patients
with proteinuria that is resistant to therapy increases Palb within
2–4 minutes of incubation [22]. We used a 50-fold dilution for
most experiments (2% vol/vol in isotonic medium). The increase
in Palb is prevented by a variety of substances, including normal
plasma [23], eicosanoids (20-hydroxyeicosatetraenoic acid, 20-
HETE, and 8,9-epoxyeicosatrieneoic acid, 8,9 EET) [24,25], cyclos-
porine A [26] and phosphatase inhibition [22] as shown in Table
2. The fact that numerous unrelated substances each provide
glomerular protection indicates the complexity of the processes
that are active in altering the glomerular permeability barrier.
MCNS has been thought to be related to a humoral
factor derived from T-cells that damages the glomerular
permeability barrier. Candidate permeability factors in MCNS
include vascular permeability factor [27]and hemopexin [28].
Vascular permeability factor is synthesized by concanavalin
A-stimulated T-lymphocytes from patients with nephrotic
syndrome. It acts on both systemic capillaries and on the
glomerular permeability barrier. Its secretion is enhanced by
interleukins (ILs) IL-2, IL-15, IL-12, and IL-18, and is inhibited
by transforming growth factor beta 1 [29,30].
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of both glomerular endothelium and podocytes. In cultured
podocytes, it activates protein kinase B and Ras homolog gene
family, member A (RhoA), and induces nephrin-dependent
reorganization of the actin cytoskeleton [31,32]. In glomerular
endothelial cell monolayers, it reduces endothelial glycocalyx
and increases albumin diffusion. [33]. Hemopexin injection in
rats causes proteinuria and glomerular foot process fusion
[34]. It is found in the urine of children with steroid-
responsive nephrotic syndrome during relapse and disappears
during remission.
A second substance, Cluster of Differentiation 80 (CD80),
has been proposed as a urinary biomarker to distinguish
between MCNS and FSGS [35]. CD80 appears to arise from
podocytes. Its expression by podocytes and shedding into
urine appears to be a manifestation of cellular response to
injury rather than the cause of injury. Urinary CD80 is not
increased in FSGS.
Circulating permeability factors in FSGS
We have carried out studies of serum and plasma from
patients with FSGS for more than 20 years. Brieﬂy, we have
found that serum, plasma, or plasma fractions increase Palb
during in vitro studies and cause proteinuria and albuminuria
in experimental models. We have tentatively identiﬁed an
IL-6 family cytokine, cardiotrophin-like cytokine-1 (CLC-1), as
a cause of glomerular injury [36]. Details of our observations
are given below. Other investigators have recently identiﬁed
soluble urokinase receptor (suPAR) in the plasma of patients
with recurrent FSGS [37]. They postulate that suPAR may be a
cause of proteinuria in FSGS. This suggestion is based on the
ﬁndings that suPAR concentrations are elevated in the pre-
transplant sera of patients with subsequent FSGS recurrence,
that urokinase receptor signaling in podocytes leads to foot
process effacement and urinary protein loss via a mechanism
that includes lipid-dependent activation of avb3 integrin, and
that transient expression of suPAR in mice leads to proteinuria
and glomerular injury. Questions arise concerning the relation-
ship between suPAR and the etiological FSGS factor, since
elevated suPAR is also found in other conditions including
diabetes mellitus, atherosclerosis, cancer, and inﬂammatory
conditions [38,39], and because levels are also elevated in
uremia due to other causes [40]. The relationship between
suPAR and the FSGS ‘‘factor’’ that we have been studying is
unknown.
In our studies of circulating substances in FSGS, we have
focused on patients who have recurrent FSGS after renal
transplantation. Proteinuria recurs following initial renal
transplantation in about 30% of patients whose underlying
diagnosis is FSGS [41]. Recurrence is much more common in
patients with a history of allograft loss due to recurrence, and
has been reported to exceed 85%. Risk factors for recurrence
include young age (i.e. children and young adults), rapid
course of primary disease (i.e. renal failure within 3 years of
diagnosis of primary disease), previous recurrence in an
allograft, and elevated permeability activity in in vitro assay
[11]. Renal allografts are often biopsied to establish a diag-
nosis in the setting of recurrent proteinuria. Recurrent FSGS,
however, is the presumptive diagnosis in patients with native
kidney FSGS and proteinuria in the early post-transplant
period. Biopsies in the ﬁrst hours after proteinuria onset
may have no morphological changes, even on electronmicroscopy [42]. Subsequent biopsies may show only foot
process effacement, but glomerulosclerosis eventually
appears unless a remission can be induced. Premature allo-
graft loss after recurrence is common [43,44].
Early recurrence of FSGS in renal allografts provides strong
evidence that the patient’s disease arises from a circulating
substance. We have used discarded ﬂuid from plasmapheresis
treatments for many of our studies because it is a source of large
amounts of plasma for studies of permeability activity and
for puriﬁcation of active components. We have surveyed the
permeability activity of sera from a wide range of patients with
nephrotic syndrome and renal disease. In our initial report,
Palb 40.5 was induced by about 30% of FSGS samples tested
[45]. In contrast, no increase in permeability was found after
incubation with the sera of patients with MCNS or de novo
membranous nephropathy after transplantation. We subse-
quently reported that the sera of 42% (11/26) of children who
presented with idiopathic nephrotic syndrome had permeability
activity and that Palb did not discriminate between steroid-
responsive and steroid-resistant patients [46]. Palb is very high in
nearly every patient with collapsing glomerulopathy [47].Insights from post-transplant recurrence of nephrotic
syndrome and FSGS
Therapy of recurrent FSGS includes early plasmapheresis is
intended to remove injurious substances(s) [48,49]. Immu-
noadsorption using Protein A or polyclonal antibodies to
human immunoglobulins has also been used in primary
or recurrent FSGS [50,51]. Many patients have a prompt
decrease in proteinuria after therapy. Possible alternative
interpretations of the observed beneﬁt of plasmapheresis
and immunoadsorption include the addition of a salutary
substance or immunomodulation. High doses of calcineurin
inhibitors, such as cyclosporine A or tacrolimus, may also
improve proteinuria and stabilize renal function in FSGS
[52,53]. Cyclosporine A does not, however, decrease circulat-
ing permeability activity in patients with FSGS (2). These
agents likely have multiple targets. Cyclosporine A prevents
the increase in Palb after incubation with FSGS serum [26,54]
and it also stabilizes the podocyte actin cytoskeleton by
blocking the effect of, calcineurin, a serine/threonine kinase,
on synaptopodin [55]. We speculate that long-term remis-
sions following relatively short courses of plasmapheresis
may be related to the protective effects of calcineurin inhibi-
tors or other agents. It is also possible that susceptibility to
injurious agents is enhanced by ischemic or immunological
injury at the time of transplant, and that recovery from these
acute insults confers some degree of resistance.
Pretransplant plasmapheresis appears to prevent or delay
recurrence in patients at high risk for relapse [56]. This response
adds support to the concept of removal of an injurious sub-
stance. Unfortunately, there is still a high risk for recurrence and
repeated plasmapheresis treatments or other therapies may be
required to prevent proteinuria and to prolong allograft function
[52,57]. Encouragement regarding potential the efﬁcacy of
pretransplant immunotherapy comes from a trial in which
transplant patients received hematopoietic donor cells following
a nonablative preconditioning regimen. Early recurrence of FSGS
was signiﬁcantly reduced, although only minimal donor-derived
engraftment occurred [58]. The precise mechanism for this
protection is not well deﬁned, but may include suppression of
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or by the chimeric state. Recent studies have documented
a mechanism by which rituximab, a monoclonal antibody to
the B cell surface marker CD20 that depletes B cells, may result
in remission of FSGS [59,60]. This agent has traditionally been
exclusively thought of as an immunomodulator. It has now been
shown to interact with sphingomyelinase of the podocyte and
prevents cellular reactions to FSGS serum [8].The FSGS factor
Approaches to the identiﬁcation of the ‘‘FSGS factor’’
Initial studies to document the presence of a plasma
permeability factor were carried out by infusing plasma into
rats. Initial success [61] was followed by discouraging varia-
bility in responses to plasma for different individuals. We have
studied the function of glomeruli after isolation from the renal
cortex [21]. Others have identiﬁed candidate proteins based on
known modiﬁers of glomerular function and have measured
these in patients with FSGS with or without recurrence [37].
Additional groups have applied proteomic techniques to
attempt to determine differences between patient and normal
plasma composition [62]. In each case, patient control groups,
including those with nephrotic syndrome due to other etiolo-
gies and those with uremia, must be studied in order to
interpret ﬁndings. A functional assay or animal model is also
required for the evaluation of the effects of candidate proteins.
Injection into animals has proven cumbersome and time
consuming. Assays based on the responses of cultured podo-
cytes depend on changes in the conﬁguration of the actin
cytoskeleton, cell morphology, and protein expression [55,63],
or measurement of the diffusional permeability of monolayers
on a permeable support [64,65]. Of note, cultured podocytes
do not form a conﬂuent monolayer and do not develop slit-
pore junctions. Further investigation will be needed before
these models are validated as means of characterizing
agents that alter glomerular permeability.
In contrast, we have been able to study glomerular barrier
function independent of the systemic humoral environment or
hemodynamic forces [21]. In addition, more chronic responses
can be studied using glomeruli from animal models of disease or
after in vivo manipulations [66–68]. Glomerular cells in isolated
glomeruli maintain their complex structure, interaction with
other glomerular cells and extracellular matrix, and synthetic
capacity [21,69], and features that are recognized as crucial to
integrity of the permeability barrier. Like other technically
demanding assays, appropriate effort and time are required to
standardize the assay. Nonetheless, several other laboratories
have successfully established this technique [66,70]. The results
of studies of isolated glomeruli are complementary to other
assays of glomerular and podocyte function.
We have used the Palb assay to verify activity during the
sequential puriﬁcation of proteins from FSGS plasma. We have
shown that the active substance in FSGS serum or plasma is a
small protein with one or more glycation sites. It has high
afﬁnity for Protein A. It has a hydrophobic domain, as evidenced
by afﬁnity in a hydrophobic interaction column. During initial
fractionation studies, we employed ammonium sulfate precipi-
tation and found that Palb activity was present in a fraction with
an apparent molecular weight of about 50 kDa. All the activity of
the original specimen was retained in this fraction. Palb activity/mg protein was enriched by more than 10,000-fold compared to
the activity of the initial plasma specimen [22,71]. More recent
studies (unpublished data) using afﬁnity chromatography and
fractionation by membrane sieving indicate that the Palb activity
is present in a fraction with an apparent molecular weight of
30 kDa or less. With progressive puriﬁcation, it is likely that
noncovalently or otherwise loosely-associated proteins are
removed, accounting for changes in the apparent molecular size
of the active substance. Recently, we have used galactose afﬁnity
puriﬁcation to enrich specimens and have employed mass
spectrometry to identify the proteins in the active fraction
[72]. Galactose afﬁnity chromatography has allowed us to
achieve a high degree of enrichment of activity in a single step.
We have subjected enriched material to mass spectro-
metry and have identiﬁed CLC-1 in the active fraction [36].
CLC-1, a member of the IL-6 family, is the only cytokine
present in patient material and not detected in normal
plasma. Further studies suggest that CLC-1 may be the
permeability factor in recurrent FSGS. It is present in active
patient plasma, it mimics the effects of FSGS plasma on Palb,
and it decreases nephrin expression by glomeruli and cul-
tured podocytes. Strikingly, a monoclonal antibody to CLC-1
blocks the Palb effect of active FSGS sera. The concentration of
CLC-1 in the circulation of patients with recurrent FSGS may
be up to 100 times higher than in normal subjects. Studies to
conﬁrm and expand these observations are ongoing.Functional properties of the FSGS permeability factor and
clinical associations
The permeability factor in FSGS plasma not only has a
strong afﬁnity for galactose, as noted above, but its activity
in the Palb assay is blocked by galactose in concentrations of
10–12 M [72]. Activity is also blocked by normal serum or
plasma [23]. Palb activity is higher in patients with severe and
rapidly progressive disease than in those with slower pro-
gression [11]. Interestingly, activity has been also been found
during post-transplant recurrence in some patients with
genetic mutations in podocyte proteins [11,73]. We can only
speculate about the relationship between podocyte mutations
and circulating permeability factors. It may be that the co-
occurrence is happenstance, i.e. two relatively common con-
ditions coexist, whereas it may be that podocyte abnormal-
ities predispose to injury by circulating substance(s) and
result in severe and recurrent renal disease. Further study
will be required to understand the relationship between these
mechanisms of glomerular injury.Implications for future therapy
We have identiﬁed a number of experimental agents that
inhibit Palb activity. These include normal plasma [23], eico-
sanoids including 20-HETE [24] or 8,9-EET [25], COX inhibi-
tors [74], oxygen radical scavengers [75], certain glycosides
of Tripterygium wilfordii [76] and cyclosporine A [54]. Each of
these prevents the increase in Palb induced by FSGS plasma. In
the future, these observations may lead to speciﬁc therapeutic
interventions in FSGS.
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Steroid therapy is a reasonable ﬁrst-line therapy and is
likely to be effective in the early stages of disease, especially
in children [10]. Cyclosporine A or Mycophenolate mofetil
(MMF) may induce remissions in additional patients, as
shown in a recent trial in children and young adults [77].
The relative effectiveness may be approximately the same.
Control of blood pressure, the use of angiotensin converting
enzyme inhibitors and/or angiotensin receptor or aldosterone
blockers and control of lipid levels with statins or ﬁbrates,
appear to provide useful adjunctive measures by which to
decrease proteinuria and slow progression. New agents that
block the effects of renin, vasopressin or endothelin may be
useful in limiting podocyte activation as well as in decreasing
proteinuria and controlling blood pressure, but these agents
have not been formally tested.
New therapies for patients with steroid-resistant or
-recurrent nephrotic syndrome/FSGS are much needed and
multicenter trials will be required. The design of these trials
will depend on understanding the mechanisms of glomerular
injury and/or the progression of renal damage. A multicenter
Phase I trial of rosiglitazone and of adalimumab has been
completed [78–80]. The related reports deﬁne the pharmaco-
kinetics of these two agents. The salutary responses in some
patients and the low incidence of adverse effects support their
potential clinical utility. Recruitment for a Phase II trial
(IND#103,147) to compare standard conservative therapy
(lisinopril, losartan and atorvastatin) versus standard therapy
plus adalimumab or standard therapy plus galactose is
complete and the study is ongoing. The rationale for using
adalimumab is that its antiﬁbrotic activity may slow down orFigure 2. Diagram depicting potential mechanisms for treatment of
FSGS and reversal of effects of circulating permeability factor.
1. Cytokine concentrations may be reduced by reducing synthesis or
secretion, by enhancing catabolism or by removal by plasmapheresis or
immunoadsorbtion. 2. Cytokine-receptor interaction may be reduced
by blocking binding sites on receptors, as may occur in the presence of
normal plasma or blocking binding sites on cytokine as with galactose.
3. Signaling pathways may be interrupted by diverse substances,
including certain eicosanoids, antioxidants and oxygen radical scaven-
gers, and by tyrosine kinase inhibitors. 4. The actin cytoskeleton may
be stabilized by calcineurin inhibitors such as cyclosporine A. 5.
Fibrosis may be limited by inhibition of the renin-angiotensin-aldos-
terone system, by blocking pro-ﬁbrotic cytokines including tumor
necrosis factor-a or transforming growth factor beta (TGF-b).prevent the progression of renal disease independent of its
effects on proteinuria. The potential efﬁcacy of galactose
therapy is supported by a case report of remission of nephro-
tic syndrome after oral galactose therapy [81] and complete
loss of FSGS permeability activity in a single patient with
post-transplant recurrence [72]. Other agents under consid-
eration or in small pilot trials include anti-TGF Transforming
growth factor beta (TGF-b) and rituximab [8,82].Summary
There is strong evidence that circulating factors may play
a role in both MCNS and FSGS in native kidneys, and in
recurrent disease in renal allografts. The precise nature of
these factors and the mechanisms by which they cause renal
injury are the subjects of intense investigation.
At the present, therapy is largely empiric and side effects
are signiﬁcant. In the near future, the mechanisms by which
the permeability factors act to cause disease may be under-
stood and rational, targeted therapy with improved efﬁcacy
and diminished toxicity may become available. Some ther-
apeutic strategies are depicted in Fig. 2. We strongly believe
that ongoing studies to deﬁne the nature of circulating
injurious factors and the mechanisms by which they alter
the permeability barrier and result in kidney injury must
continue. Multicenter cooperative studies will be required to
test the efﬁcacy of novel therapies. Broad participation in
clinical trials will be essential for treating patients with FSGS
in native kidneys in order to prevent progression, and prior
to and following transplantation to permit long-term graft
function and return to health.Conﬂict of Interest
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